EGFR targeted therapy: view from biological standpoint

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Activating mutations in the epidermal growth factor receptor (EGFR) kinase domain are key drivers in non-small cell lung cancer (NSCLC).
• EGFR kinase domain mutants are essential for cancer cell survival, unlike wild-type (wt) EGFR.
• Tumors with EGFR mutations show sensitivity to targeted therapies, mirroring patient responses.

Purpose of the Study:

• To investigate the role of EGFR kinase domain mutations versus wt EGFR in lung tumorigenesis.
• To differentiate the therapeutic implications of targeting mutant EGFR versus wt EGFR in NSCLC.

Main Methods:

• Induction of EGFR kinase domain mutants in murine lung epithelium in vivo.
• Observation of tumor development and dependence on sustained mutant EGFR expression.
• Comparison of tumor response to EGFR targeted therapy in mutant vs. wt EGFR models.

Main Results:

• EGFR kinase domain mutants induced adenocarcinoma with bronchioloalveolar carcinoma features in mice.
• These tumors were critically dependent on sustained mutant EGFR expression for maintenance.
• Murine tumors with EGFR mutations responded to targeted therapy, similar to NSCLC patients.
• Overexpression of wt EGFR did not appear to be transforming in murine lungs.

Conclusions:

• EGFR targeted therapy in NSCLC should be stratified into "EGFR mutant targeted therapy" and "wt EGFR targeted therapy".
• "EGFR mutant targeted therapy" targets an oncogene essential for tumor initiation and maintenance, yielding better clinical outcomes.
• "wt EGFR targeted therapy" targets a proto-oncogene not directly involved in tumor initiation, with less dramatic responses.